BioSpace News Archive

- Twenty-five percent absolute survival benefit at 5 years for patients receiving stereotactic ablative radiotherapy to all metastatic lesions - Growing body of evidence that addition of SABR can increase overall survival rates for patients with metastatic disease against standard-of-care (SOC) - SOC is defined as palliative radiotherapy, if indicated, and further chemotherapy at the discretion of the medical oncologist

Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH), (OTC:MCUJF), a pharmaceutical company, is pleased to announce the launch of a direct to patient online pharmacy program for the distribution of ZYPITAMAGTM in the United States.

KIYATEC, Inc. today announced that the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS) has joined the growing roster of institutions participating in its 3D-PREDICT clinical study to validate the company’s test as a patient-specific predictor of response to recommended drug therapies for patients with ovarian cancer. “Ovarian cancer patients and clinicians do

Teknova , a leading ISO 13485-certified manufacturer of cell culture media and supplements, protein purification buffers, and molecular biology reagents, is pleased to announce the appointment of Stephen Gunstream as chief executive officer. Stephen has nearly 20 years of experience i

Espero BioPharma, Inc. is focused on the development of drugs for the treatment of cardiorenal diseases. The company, a private Delaware corporation, is the result of a 2017 business combination between Espero Pharmaceuticals, Inc. and Armetheon, Inc. The company’s portfolio of products includes: (i) tecarfarin, a Phase III-ready oral a

Rapha Capital Management, LLC ( https://raphacap.com ), an investment management firm located in Miami, Florida , through Rapha Capital Investment XI, LLC (“RCI XI”) (an entity managed by Rapha Capital), participated in Poseida Therapeutics Inc.'s Series D financing, led by funds advised by Fidelity Management Research Company, LLC. RCI XI i

PPD, Inc. (Nasdaq: PPD ) has expanded its laboratory test portfolio by adding five new molecular, serology and functional assays designed expressly for COVID-19 vaccine and therapy development programs. These assays have been developed by PPD ® Laboratories’ bioanalytical, biomarker and vaccines sciences labs to run on multiple assay platforms and are compatible with high-throughput liquid handling so they can support

Vertex Foundation Announces $1.5 Million Gift to Boston University’s New Center for Antiracist Research

Oral presentation and poster detail DR-18’s ability to re-animate exhausted NK cells, bias differentiation of T cells toward highly active effectors and expand the population of critical immune cells inside the tumor microenvironment

Canada has long been considered a top global jurisdiction for new medicine launches. However, a new report published by Life Sciences Ontario shows that new medicine launches in Canada fell dramatically in 2019.